Breaking News Instant updates and real-time market news.

A

Agilent

$77.54

-2.855 (-3.55%)

, MRK

Merck

$77.50

-1.01 (-1.29%)

20:07
04/16/19
04/16
20:07
04/16/19
20:07

Agilent receives FDA approval for PD-L1 IHC 22C3 pharmDx assay

Agilent Technologies (A) announced that the FDA has updated its approval of the company's PD-L1 IHC 22C3 pharmDx assay. The assay can now be used as a companion diagnostic to identify a broader range of patients with stage III or metastatic non-small cell lung cancer, or NSCLC, for first-line treatment with KEYTRUDA, a targeted anti-PD-1 therapy manufactured by Merck (MRK). The FDA previously approved the assay to identify metastatic NSCLC patients whose tumors express PD-L1 Tumor Proportion Score of 50% or more for first-line treatment with KEYTRUDA. Now, patients with stage III NSCLC who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 TPS of 1% or more are eligible for first-line treatment. This expanded indication enables pathologists to identify a larger population of previously untreated patients who are now eligible for treatment with KEYTRUDA.

A

Agilent

$77.54

-2.855 (-3.55%)

MRK

Merck

$77.50

-1.01 (-1.29%)

  • 17

    Apr

  • 30

    Apr

  • 06

    May

  • 14

    May

  • 18

    May

  • 03

    Jun

  • 17

    Jun

  • 20

    Jun

  • 16

    Jul

  • 06

    Aug

  • 20

    Sep

A Agilent
$77.54

-2.855 (-3.55%)

03/26/19
COWN
03/26/19
NO CHANGE
Target $90
COWN
Outperform
Agilent price target raised to $90 from $80 at Cowen
Cowen analyst Doug Schenkel maintained an Outperform rating on Agilent and raised his price target to $90 from $80 after hosting meetings with management. In a research note to investors, Schenkel says he came away from the meetings with incremental confidence in the company's ability to continue posting above-peer average top and bottom line growth in the near- and long-term. He believes shares are worth $(0, and could see further upside as management continues to execute relative to expectations.
03/15/19
UBSW
03/15/19
INITIATION
Target $92
UBSW
Buy
Agilent initiated with a Buy at UBS
UBS analyst Daniel Brennan started Agilent Technologies with a Buy rating and $92 price target. The analyst says stronger revenue growth coupled with rising incremental margins support his earnings forecasts being 2%-3% ahead of consensus. Further, "more aggressive" acquisition activity or share buybacks could drive "material further" earnings upside, Brennan tells investors in a research note. He believes Agilent has "significant balance sheet optionality."
02/21/19
BARD
02/21/19
NO CHANGE
Target $82
BARD
Outperform
Agilent price target raised to $82 from $77 at Baird
Baird analyst Catherin Ramsey-Schulte raised her price target on Agilent to $82 from $77 following Q4 results. The analyst said the shares may be weak following the report given the stock's recent run up and the weakness in LSAG growth. She believes the underlying business remains healthy and continues to see upside from end market strength, new product introductions, and potential incremental capital deployment. Ramsey-Schulte reiterated her Outperform rating on Agilent shares.
02/21/19
DBAB
02/21/19
NO CHANGE
Target $90
DBAB
Buy
Agilent price target raised to $90 from $85 at Deutsche Bank
Deutsche Bank analyst Dan Leonard raised his price target for Agilent Technologies to $90 and reiterates a Buy rating on the shares following the company's fiscal Q1 results and a fiscal 2019 earnings guidance increase. The analyst continues to believe Agilent has more opportunities for growth, margin expansion, and capital deployment than peers.
MRK Merck
$77.50

-1.01 (-1.29%)

03/20/19
SBSH
03/20/19
NO CHANGE
SBSH
Bayer shares likely to remain 'depressed' pending trial success, says Citi
While sentiment will "clearly take a knock" at the second Roundup trial going against Bayer (BAYRY), both verdicts were delivered by juries in California and EUR 22B of litigation risk is already priced into the shares, Citi analyst Peter Verdult tells investors in a research note. The analyst says his legal checks continue to instruct him to be more focused on the upcoming Hall vs. Monsanto trial being held in St Louis from April 1. He says that verdict will better determine whether his estimate of a potential settlement liability of $1B-$6B needs to be refined. However, Bayer shares will "likely remain depressed" until there is evidence of the company prevailing in one or more of the six cases to go to trial in 2019, Verdult contends. He keeps a Buy rating on the stock but prefers other Pharma plays AstraZeneca (AZN), Sanofi (SNY), Novartis (NVS) and Merck (MRK).
03/13/19
CANT
03/13/19
NO CHANGE
Target $95
CANT
Overweight
Merck opportunity in China is underappreciated, says Cantor Fitzgerald
After taking a deeper look at the Chinese PD-1 market, Cantor Fitzgerald analyst Louise Chen believes it could equate to billions of sales that are not yet in the forecasts for Merck's Keytruda. She thinks the peak sales potential of PD-1s in China remains underappreciated. China's pharma market can grow to $225B by 2025, which would support a growing PD-1/PD-L1 market, Chen tells investors in a research note titled "Deep Dive into China: A Complicated but Underappreciated Opportunity." The analyst keeps an Overweight rating on Merck with a $95 price target.
03/11/19
WBLR
03/11/19
NO CHANGE
WBLR
Outperform
William Blair sum-of-the-parts analysis yields $19.80 value for Pfenex
The majority of Pfenex (PFNX) investor focus has been placed on lead asset PF708, the therapeutic equivalent product candidate to Forteo, William Blair analyst Andy Hsieh tells investors in a research note, citing his talks with clients. The analyst, however, sees "potential for significant value" from the company's collaboration with Jazz Pharmaceuticals (JAZZ). The deal with Jazz could provide patients with an alternative to Erwinaze/Erwinase, which currently suffers from significant supply constraints, and CRM197, a carrier protein that is incorporated as an adjuvant in several vaccine candidates, including Merck's (MRK) pneumococcal vaccine, V114, Hsieh writes. Based on these royalties, the analyst conducted a sum-of-the-parts analysis for Pfenex based on discounted cash flow, and the resulting net present value yielded a value of $19.80 per share. The stock closed Monday at $4.26. The analyst believes the company's "value-creating" catalysts this year, including milestone payment from Jazz for the successful tech transfer of PF743 and PF745 and the approval of PF708, coupled with his valuation analysis, affirm his bullish thesis. Hsieh believes Pfenex shares offer one of the best risk/reward symmetries in small-cap biotech and reiterates an Outperform rating on the name.
02/22/19
CANT
02/22/19
INITIATION
Target $95
CANT
Overweight
Merck initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen started Merck with an Overweight rating and $95 price target. The company's sales growth across oncology, vaccines, animal health, and select hospital/specialty care products, as well as its margin expansion opportunities, are underappreciated at current share levels, Chen tells investors in a research note. She expects upward earnings revisions and multiple expansion in 2019 to drive Merck shares higher.

TODAY'S FREE FLY STORIES

PYPL

PayPal

$107.18

0.27 (0.25%)

08:30
04/25/19
04/25
08:30
04/25/19
08:30
Recommendations
PayPal analyst commentary  »

PayPal price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 14

    May

  • 22

    May

  • 03

    Jun

  • 11

    Jun

LUV

Southwest

$52.92

0.11 (0.21%)

08:30
04/25/19
04/25
08:30
04/25/19
08:30
Hot Stocks
Southwest sees FY19 CapEx $1.9B-$2B »

Based on aircraft…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 13

    Nov

JMIA

Jumia Technologies

$37.15

1.18 (3.28%)

, PINS

Pinterest

$26.80

0.99 (3.84%)

08:30
04/25/19
04/25
08:30
04/25/19
08:30
Options
Three new option listings and one option delisting on April 25th »

New option listings for…

JMIA

Jumia Technologies

$37.15

1.18 (3.28%)

PINS

Pinterest

$26.80

0.99 (3.84%)

ZM

Zoom Video

$63.32

-5.735 (-8.31%)

USG

USG

$43.49

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLAB

Silicon Labs

$110.04

16.41 (17.53%)

08:29
04/25/19
04/25
08:29
04/25/19
08:29
Recommendations
Silicon Labs analyst commentary  »

Silicon Labs price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PFE

Pfizer

$39.39

-0.02 (-0.05%)

08:29
04/25/19
04/25
08:29
04/25/19
08:29
Conference/Events
Pfizer management to meet with Evercore ISI »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 30

    Apr

  • 02

    May

  • 06

    May

  • 13

    May

  • 18

    May

  • 31

    May

LUV

Southwest

$52.92

0.11 (0.21%)

08:29
04/25/19
04/25
08:29
04/25/19
08:29
Hot Stocks
Southwest sees FY19 CASM ex-fuel up 5.5%-6.5% »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 13

    Nov

LUV

Southwest

$52.92

0.11 (0.21%)

08:28
04/25/19
04/25
08:28
04/25/19
08:28
Hot Stocks
Southwest sees Q2 CASM ex-fuel up 10.5%-12.5% »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 13

    Nov

APD

Air Products

$199.50

2.83 (1.44%)

08:27
04/25/19
04/25
08:27
04/25/19
08:27
Downgrade
Air Products rating change  »

Air Products downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MKTX

MarketAxess

$264.37

1.77 (0.67%)

08:27
04/25/19
04/25
08:27
04/25/19
08:27
Conference/Events
MarketAxess management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

LTXB

LegacyTexas Financial

$38.05

-3.13 (-7.60%)

08:26
04/25/19
04/25
08:26
04/25/19
08:26
Upgrade
LegacyTexas Financial rating change  »

LegacyTexas Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    May

  • 20

    May

LUV

Southwest

$52.92

0.11 (0.21%)

08:26
04/25/19
04/25
08:26
04/25/19
08:26
Hot Stocks
Southwest sees Q2 fuel efficiency flat to down 1% »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 13

    Nov

LUV

Southwest

$52.92

0.11 (0.21%)

08:25
04/25/19
04/25
08:25
04/25/19
08:25
Hot Stocks
Southwest expects Q2 RASM to increase 5.5%-7.5% »

The company said,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 15

    May

  • 21

    May

  • 13

    Nov

YNDX

Yandex

$37.61

-0.17 (-0.45%)

08:24
04/25/19
04/25
08:24
04/25/19
08:24
Earnings
Yandex sees FY19 ruble-based revenues excluding Yandex Market up 30%-34% »

Consensus for FY19…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

YNDX

Yandex

$37.61

-0.17 (-0.45%)

08:23
04/25/19
04/25
08:23
04/25/19
08:23
Earnings
Yandex reports Q1 EPS 16c, consensus 26c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

LEN

Lennar

$52.63

0.17 (0.32%)

08:23
04/25/19
04/25
08:23
04/25/19
08:23
Conference/Events
Lennar management to meet with KeyBanc »

Visit with management at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

ASPS

Altisource

$23.68

-0.08 (-0.34%)

08:22
04/25/19
04/25
08:22
04/25/19
08:22
Earnings
Altisource reports Q1 adjusted EPS 48c vs. 48c a year ago »

Altisource Portfolio…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

FB

Facebook

$182.64

-1.13 (-0.61%)

08:21
04/25/19
04/25
08:21
04/25/19
08:21
Recommendations
Facebook analyst commentary at Wedbush »

Facebook price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Apr

  • 30

    May

  • 03

    Jun

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:21
04/25/19
04/25
08:21
04/25/19
08:21
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UTL

Unitil

$54.18

0.43 (0.80%)

08:20
04/25/19
04/25
08:20
04/25/19
08:20
Earnings
Unitil reports Q1 EPS $1.78 with items, consensus $1.25 »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

HMI

Huami

$11.05

-1.355 (-10.93%)

08:20
04/25/19
04/25
08:20
04/25/19
08:20
Syndicate
Huami 7.93M share Secondary priced at $9.75 »

Morgan Stanley, Credit…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

$DJU

DJ Utility Average

$0.00

(0.00%)

08:20
04/25/19
04/25
08:20
04/25/19
08:20
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSIC

Henry Schein

$64.15

0.92 (1.46%)

08:20
04/25/19
04/25
08:20
04/25/19
08:20
Hot Stocks
Henry Schein, MindChild Medical announce distribution, supply agreement »

Henry Schein Medical, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    May

  • 22

    May

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:20
04/25/19
04/25
08:20
04/25/19
08:20
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$199.53

1.71 (0.86%)

08:20
04/25/19
04/25
08:20
04/25/19
08:20
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$78.88

0.03 (0.04%)

08:19
04/25/19
04/25
08:19
04/25/19
08:19
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.